Cost-Effectiveness of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation
-
- Amanda R. Harrington
- From the Department of Pharmacy Practice and Science, College of Pharmacy, University of Arizona, Tucson, AZ.
-
- Edward P. Armstrong
- From the Department of Pharmacy Practice and Science, College of Pharmacy, University of Arizona, Tucson, AZ.
-
- Paul E. Nolan
- From the Department of Pharmacy Practice and Science, College of Pharmacy, University of Arizona, Tucson, AZ.
-
- Daniel C. Malone
- From the Department of Pharmacy Practice and Science, College of Pharmacy, University of Arizona, Tucson, AZ.
説明
<jats:sec> <jats:title>Background and Purpose—</jats:title> <jats:p>To estimate the cost-effectiveness of stroke prevention in patients with nonvalvular atrial fibrillation by using novel oral anticoagulants apixaban 5 mg, dabigatran 150 mg, and rivaroxaban 20 mg compared with warfarin.</jats:p> </jats:sec> <jats:sec> <jats:title>Methods—</jats:title> <jats:p> A Markov decision-analysis model was constructed using data from clinical trials to evaluate lifetime costs and quality-adjusted life-years of novel oral anticoagulants compared with warfarin. The modeled population was a hypothetical cohort of 70-year-old patients with nonvalvular atrial fibrillation, increased risk for stroke (CHADS <jats:sub>2</jats:sub> ≥1), renal creatinine clearance ≥50 mL/min, and no previous contraindications to anticoagulation. The willingness-to-pay threshold was $50 000/quality-adjusted life-years gained. </jats:p> </jats:sec> <jats:sec> <jats:title>Results—</jats:title> <jats:p>In the base case, warfarin had the lowest cost of $77 813 (SD, $2223), followed by rivaroxaban 20 mg ($78 738±$1852), dabigatran 150 mg ($82 719±$1959), and apixaban 5 mg ($85 326±$1512). Apixaban 5 mg had the highest quality-adjusted life-years estimate at 8.47 (SD, 0.06), followed by dabigatran 150 mg (8.41±0.07), rivaroxaban 20 mg (8.26±0.06), and warfarin (7.97±0.04). In a Monte Carlo probabilistic sensitivity analysis, apixaban 5 mg, dabigatran 150 mg, rivaroxaban 20 mg, and warfarin were cost-effective in 45.1%, 40%, 14.9%, 0% of the simulations, respectively.</jats:p> </jats:sec> <jats:sec> <jats:title>Conclusions—</jats:title> <jats:p>In patients with nonvalvular atrial fibrillation and an increased risk of stroke prophylaxis, apixaban 5 mg, dabigatran 150 mg, and rivaroxaban 20 mg were all cost-effective alternatives to warfarin. The cost-effectiveness of novel oral anticoagulantss was dependent on therapy pricing in the United States and neurological events associated with rivaroxaban 20 mg.</jats:p> </jats:sec>
収録刊行物
-
- Stroke
-
Stroke 44 (6), 1676-1681, 2013-06
Ovid Technologies (Wolters Kluwer Health)